Please ensure Javascript is enabled for purposes of website accessibility

Why ViewRay Stock Is Bouncing Back Today

By Brian Feroldi – Updated Aug 12, 2019 at 11:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares start to rebound after a gut-wrenching decline.

What happened

Shares of ViewRay (VRAY 1.31%), a medical equipment provider that focuses on radiation therapy, rose 16% in early morning trading on Monday on higher-than-normal volume. There wasn't a single press release, Securities and Exchange Commission filing, or analyst upgrade released today that can help explain the move. The gains might be attributable to short-covering after Friday's horrific decline, or buying from investors who see value in the share price today.

So what

ViewRay's stock was cut in half last week after the company reported weak second-quarter results and slashed its full-year guidance. Management also announced that its CFO was looking for an exit, which doesn't exactly inspire long-term confidence.

More than 22 million shares of ViewRay's stock were sold short as of July 31, so short-sellers earned a tidy profit from the stock's huge fall. It's possible that today's double-digit recovery is traceable to profit-taking by the shorts, who have to buy the shares on the open market in order to exit their position.

Stock chart with price heading down and then up

Image source: Getty Images.

Another possibility is that some investors still believe in the viability of the business and think that the stock is a steal at today's prices. Analysts at Jefferies, Northland Securities, and B. Riley FBR all came to ViewRay's defense after the huge drop and issued price targets that all imply huge upside from today's price.

Regardless of the underlying cause, shares are on the upswing today. 

Now what

ViewRay is now under tremendous pressure to get its sales trajectory back on track. That won't be easy since its MRIdian Linac System costs several million dollars and is likely to be very hard to sell, but the company doesn't really have any other options. Its cash balance of $122 million won't last long, since the business is producing a quarterly net loss of about $31 million. Management is going to have to raise additional funds at some point, and it will be extremely painful to do so at today's depressed prices.

ViewRay might be a steal today, but I continue to believe that this stock is too risky to touch. 

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ViewRay, Inc. Stock Quote
ViewRay, Inc.
VRAY
$3.87 (1.31%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.